Boston Scientific raises FY25 adjusted EPS view to $3.02-$3.04 from $2.95-$2.99

Consensus $2.98. Raises FY25 revenue view to up 20% from up 18%-19%. The company said, “The company estimates net sales growth for the full year 2025, versus the prior year period, to be approximately 20 percent on a reported basis and approximately 15.5 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.97 to $2.01 and estimates adjusted EPS, excluding certain charges, of $3.02 to $3.04.”